Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | C1R | P00736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251669 | 0.90 | ELANE (0.61) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL321784 | 0.89 | ELANE (0.62) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL692456 | 0.89 | ELANE (0.62) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL23668747 | 0.84 | ELANE (0.69) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL6565079 | 0.82 | MAPT (0.54) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL10780103 | 0.80 | ELANE (0.77) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2704120 | 0.80 | C1R (0.68) | ELANEKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6594806 | 0.79 | ELANE (0.65) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL10781834 | 0.79 | ELANE (0.74) | ELANEKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL6564016 | 0.77 | ALDH1A1 (0.56) | ELANEKMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| CN-103080111-B | Imidazopyridine derivatives, its preparation method and therapeutical uses thereof | 赛诺菲 | 2016-06-15 | — | — | CN | disclosed |
| US-9206177-B2 | Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists | SANOFI (FR) | 2015-12-08 | — | — | US | disclosed |
| US-9206177-B2 | Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists | SANOFI (FR) | 2015-12-08 | — | — | US | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| EP-2590976-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| CN-103080111-A | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI SA | 2013-05-01 | — | — | CN | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-8008321-B2 | Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | ELANE 4582/4885KMT2A 1185/4885MEN1 1810/4885 |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | CYP3A5, CYP4B1, CYP3A7 | ELANE 4280/4885KMT2A 2940/4885MEN1 919/4885 |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | ELANE 1961/4885KMT2A 3395/4885MEN1 621/4885 |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | P2RX6, IL5, ATIC | ELANE 4340/4885KMT2A 3462/4885MEN1 1729/4885 |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, INMT, IDO1 | ELANE 4664/4885KMT2A 1538/4885MEN1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.